With an increasing incidence of endometrial cancer worldwide, fertility-sparing management for young patients with early-stage endometrioid endometrial cancer (EEC) and atypical hyperplasia (EAH) has turned into an important issue.
The current situation of the levonorgestrel intrauterine system (LNG-IUS) in conservative treatment for patients with early-stage endometrial cancer and atypical hyperplasia than 100 for EEC patients. In a systemic analysis of 189 EAH patients from 14 studies, LNG-IUS achieved a higher pooled regression rate compared with oral progestogens (pooled rate, 90% vs. 69%; p=0.03) [6] . Another retrospective study [7] on LNG-IUS showed response rates of 80% (95% confidence interval [CI]=52-96) in EAH patients (n=15), 67% (95% CI=30-93) in EEC G1 (n=9) and 75% (95% CI=35-97) in EEC G2 patients (n=8). Median uterine diameter was 1.3 cm larger in women who did not respond to LNG-IUS (p=0.04). The RCOG guideline recommend LNG-IUS as the first-line conservative treatment for endometrial hyperplasia and EAH [8] . National Comprehensive Cancer Network added LNG-IUS as one of the options for fertility preserving treatment for EEC G1 patients since 2014.
In this issue of the Journal of Gynecologic Oncology, Leone Roberti Maggiore et al. [9] reported the effect of LNG-IUS on conservative treatment on 28 EAH, 16 EEC G1 and 4 EEC G2 patients with a relatively long follow-up period (82.6±47.2 months). In their study, LNG-IUS alone achieved a CR rate of 89.3% (25/28) in EAH patients, 81.3% (13/16) in EEC G1 patients, and 75% (3/4) in EEC G2 patients. Despite the retrospective nature, this is to date the largest case series investigating the efficacy and fertility outcomes of LNG-IUS in patients of reproductive age affected by EEC/EAH, which provides evidence to the further use of LNG-IUS in EAH/EEC patients.
Several aspects should be paid attention regarding the use of LNG-IUS in conservative treatment of EAH and EEC patients:
Firstly, LNG-IUS alone should be used carefully in patients with enlarged uterine cavity [7] . The local releasing levonorgestrel can only reach the endometrium near the device, therefore, may fail to treat the endometrial lesion beyond LNG-IUS reachable range in an enlarged uterine cavity. In such case, systemic therapies such as oral progestins or GnRH-a combined with LNG-IUS should be suggested [10, 11] .
Secondly, although the effect of LNG-IUS on EAH is promising, the effect of LNG-IUS alone on EEC G1 still warrants further investigation. The reported CR rate using LNG-IUS alone in EEC varied from 22% [12] to 81.3% in the present study. Given the retrospective nature of the studies, we cannot yet tell which EEC G1 patients are most appropriate for LNG-IUS treatment.
Thirdly, due to the modest effect of progestin on EEC G2 patients, cautions should be made when LNG-IUS is used as fertility-sparing regimen for this advanced subtype.
There are several clinical trials carried on investigating the effect of LNG-IUS alone or in combination with oral progestins on EEC/EAH patients (NCT03241914, NCT03463252, and NCT03241888). The results of these trials might provide us further information regarding the use of LNG-IUS in EEC/EAH patients.
